Vaxcyte Future Growth

Future criteria checks 0/6

Vaxcyte's earnings are forecast to decline at 1% per annum while its annual revenue is expected to grow at 70.1% per year. EPS is expected to grow by 3.1% per annum.

Key information

-1.0%

Earnings growth rate

3.1%

EPS growth rate

Biotechs earnings growth	24.0%
Revenue growth rate	70.1%
Future return on equity	n/a
Analyst coverage	Good
Last updated	13 Apr 2024

Recent future growth updates

Recent updates

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Dec 27

We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely

Sep 12

Here's Why We're Not Too Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Situation

May 30

Vaxcyte completes enrollment in phase 2 portion of study of pneumonia vaccine candidate

Jul 12

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Feb 25

We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely

Nov 08

We're Interested To See How Vaxcyte (NASDAQ:PCVX) Uses Its Cash Hoard To Grow

Jul 26

We're Interested To See How Vaxcyte (NASDAQ:PCVX) Uses Its Cash Hoard To Grow

Apr 12

Earnings and Revenue Growth Forecasts

NasdaqGS:PCVX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	21	-549	-404	-260	7
12/31/2025	N/A	-509	-404	-207	8
12/31/2024	N/A	-464	-320	-386	8
12/31/2023	N/A	-402	-365	-297	N/A
9/30/2023	N/A	-300	-245	-233	N/A
6/30/2023	N/A	-265	-220	-214	N/A
3/31/2023	N/A	-245	-199	-191	N/A
12/31/2022	N/A	-223	-176	-171	N/A
9/30/2022	N/A	-174	-163	-156	N/A
6/30/2022	N/A	-143	-153	-146	N/A
3/31/2022	N/A	-118	-144	-136	N/A
12/31/2021	N/A	-100	-128	-121	N/A
9/30/2021	N/A	-92	-87	-81	N/A
6/30/2021	N/A	-87	-70	-66	N/A
3/31/2021	N/A	-83	-48	-46	N/A
12/31/2020	N/A	-89	-48	-47	N/A
9/30/2020	N/A	-83	-52	-50	N/A
6/30/2020	N/A	-73	-48	-47	N/A
3/31/2020	N/A	-64	-53	-51	N/A
12/31/2019	N/A	-50	-48	-47	N/A
12/31/2018	N/A	-29	-32	-30	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PCVX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PCVX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PCVX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PCVX is forecast to have no revenue next year.

High Growth Revenue: PCVX is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PCVX's Return on Equity is forecast to be high in 3 years time

Vaxcyte Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased by 7.8% to US$71.14

Price target increased to US$60.50

Price target increased to US$56.00

Consensus forecasts updated

Recent updates

President & CFO notifies of intention to sell stock

Vaxcyte, Inc., Annual General Meeting, Jun 06, 2024

President & CFO notifies of intention to sell stock

New major risk - Revenue and earnings growth

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

New major risk - Revenue and earnings growth

President & CFO notifies of intention to sell stock

Vaxcyte, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

President & CFO notifies of intention to sell stock

Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer

Price target increased by 7.8% to US$71.14

Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise

Co-Founder notifies of intention to sell stock

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Senior VP notifies of intention to sell stock

Vaxcyte, Inc. Announces the Publication of the Results from the VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in the Journal The Lancet Infectious Diseases

Vaxcyte, Inc. Appoints Jacks Lee to Board of Directors

President & CFO notifies of intention to sell stock

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

President & CFO notifies of intention to sell stock

Vaxcyte, Inc. Announces FDA Clearance of Investigational New Drug Application for Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

Co-Founder notifies of intention to sell stock

We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Situation

Vaxcyte, Inc. to Report Q4, 2022 Results on Feb 27, 2023

President exercised options to buy US$1.1m worth of stock.

Vaxcyte’S VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults

Executive VP & COO exercised options to buy US$5.1m worth of stock.

We Think Vaxcyte (NASDAQ:PCVX) Can Afford To Drive Business Growth

Vaxcyte, Inc. Announces Executive Changes, Effective January 1, 2023

Independent Director exercised options and sold US$131k worth of stock

High number of new directors

Price target increased to US$60.50

Independent Director exercised options and sold US$147k worth of stock

Price target increased to US$56.00

Vaxcyte, Inc. Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24 Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64

Co-Founder & VP of Research notifies of intention to sell stock

Vaxcyte, Inc. Announces Executive Appointments

Vaxcyte appoints new CBO, CMO

Co-Founder notifies of intention to sell stock

Co-Founder & VP of Research notifies of intention to sell stock

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older

Co-Founder notifies of intention to sell stock

Co-Founder & VP of Research notifies of intention to sell stock

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Insider notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

President & CFO notifies of intention to sell stock

Vaxcyte, Inc. Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-Of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of Vax-24 in Adults

Vaxcyte completes enrollment in phase 2 portion of study of pneumonia vaccine candidate

Executive VP & COO notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Co-Founder & VP of Research notifies of intention to sell stock

Insider notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

High number of new directors

Co-Founder notifies of intention to sell stock

Vaxcyte, Inc., Annual General Meeting, Jun 01, 2022

Co-Founder & VP of Research notifies of intention to sell stock

Vaxcyte, Inc. Announces Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in Adults

President & CFO notifies of intention to sell stock

Insider notifies of intention to sell stock

Chief Operating Officer notifies of intention to sell stock

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Vaxcyte, Inc. Announces the First Participants Dose in the Phase 1/2 Clinical Study of VAX-24

Vaxcyte, Inc. to Report Q4, 2021 Results on Feb 28, 2022